Fludeoxyglucose F-18 300 mCi/mL (Fludeoxyglucose F-18 INJECTION) 300 mCi/mL

Fludeoxyglucose F-18 300 mCi/mL is a radiopharmaceutical injection used for diagnostic imaging. This intravenous solution is designed to aid in the visualization of metabolic processes within the body.

Strength

300 mCi/mL

Pack Size

30 mL in 1 VIAL, MULTI-DOSE (16129-001-30)

Manufacturer / TM Owner

Pharmalogic South Carolina, LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fludeoxyglucose F-18 is primarily used in positron emission tomography (PET) scans. This radiopharmaceutical helps in identifying areas of high metabolic activity, which can be useful in various diagnostic procedures. What is Fludeoxyglucose F-18 used for? It is often employed to detect and monitor conditions that affect metabolic activity, such as certain types of cancer or neurological disorders.

Side Effects

Fludeoxyglucose F-18 works by being absorbed by cells with high metabolic rates. This can help highlight areas of interest during imaging. Common effects may include temporary discomfort at the injection site, but these are generally mild and short-lived.

Precautions & Warnings

Handling Fludeoxyglucose F-18 requires careful attention due to its radioactive nature. It should be administered by trained healthcare professionals in a controlled environment. Proper disposal procedures must be followed to ensure safety.

Avoid Interactions

Fludeoxyglucose F-18 may interact with other medications or substances. It is important to inform healthcare providers about any current medications or health conditions before administration. Alcohol and certain foods may also affect the results of the diagnostic procedure.

Frequently Asked Questions

Fludeoxyglucose F-18 is used in PET scans to visualize areas of high metabolic activity, often for diagnostic purposes.

Fludeoxyglucose F-18 is administered intravenously by trained healthcare professionals.

Common effects may include temporary discomfort at the injection site, but these are generally mild and short-lived.

Yes, due to its radioactive nature, Fludeoxyglucose F-18 should be handled with care and administered by trained professionals.

Yes, it may interact with other medications or substances, so it is important to inform healthcare providers about any current medications or health conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.